BRAINSTORM CELL THERAPEUTICS INC. Litigation

May 4, 2026

Motion for Class Certification

The plaintiffs have asked the court to approve the lawsuit to proceed as a class action on behalf of a group of investors. The judge will decide whether the case meets the requirements for class certification and which investors and claims may be included.

Sep 15, 2025

Motion to Dismiss Denied in Part

The court has determined that plaintiffs have adequately alleged some of their claims, but have failed to adequately allege other claims. The judge has therefore denied in part the motion to dismiss filed by defendants and written an order stating which claims are dismissed and which remain. The case will proceed and parties will litigate the remaining claims.

May 31, 2024

Motion to Dismiss

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

Apr 1, 2024

First Amended Complaint

A new complaint has been filed on behalf of certain investors in BRAINSTORM CELL THERAPEUTICS INC.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Jan 22, 2024

Appointment of Lead Plaintiff

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Nov 1, 2023

First Filed Complaint

A securities fraud class action complaint has been filed on behalf of certain investors in BRAINSTORM CELL THERAPEUTICS INC..